Cisplatin-Eugenol Hybrid Compound for Resistant Tumor Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cisplatin-based treatments for cancer are toxic and ineffective against certain types of tumors, particularly ovarian cancer, and there is a need for more effective drugs against resistant and recurrent tumors.
Innovation Solution
A compound comprising a covalently connected cisplatin and eugenol component, synthesized through a method involving the addition of eugenol and a base to water, followed by cisplatin, to form a novel cisplatin analogue with enhanced anti-cancer properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cisplatin is used to treat cancer, then anti-cancer effectiveness is improved, but kidney toxicity increases
Solution Approach 1:
The patent combines cisplatin with eugenol through a covalent linker to create a hybrid molecule that integrates the anti-cancer properties of cisplatin with the protective and potentiating effects of eugenol, thereby maintaining efficacy while reducing toxicity
Solution Approach 2:
The invention creates a composite molecular structure where cisplatin and eugenol are chemically linked, forming a new compound that exhibits properties of both parent molecules, including enhanced anti-cancer activity and reduced side effects
2Reliability
If cisplatin is used to treat cancer, then tumor cell killing is improved, but resistance in certain tumor types (e.g., ovarian cancer) develops
Solution Approach 1:
By merging cisplatin with eugenol in a single molecular entity, the compound overcomes tumor resistance mechanisms that would normally block cisplatin action, particularly in ovarian cancer cells where sequential treatment is required
Solution Approach 2:
The invention changes the chemical and biological parameters of the cisplatin molecule by attaching eugenol, which modifies the compound's interaction with tumor cells and overcomes resistance mechanisms
3Reliability
If sequential combination of cisplatin and eugenol is used for ovarian cancer, then effectiveness is improved, but treatment complexity increases
Solution Approach 1:
The patent merges two separate treatment steps (cisplatin followed by eugenol) into a single administered compound, simplifying the treatment protocol while maintaining the synergistic effectiveness against ovarian cancer
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new compound, eugenoplatin, demonstrates potent anti-cancer activity against various cancer types, including breast, ovarian, and other resistant tumors, with reduced toxicity to normal cells and the ability to target cancer stem cells and induce DNA damage.
Implementation Method 1
A compound comprising a cisplatin component and a eugenol component which are covalently connected via a linker
Data Source
AI summary
The present invention relates to a compound comprising a cisplatin component and a eugenol component. The present invention further relates to a synthesis method of said compound, pharmaceutical compositions comprising the compound and its medical uses. The present invention further relates to a method of treatment of cancer.